Overview

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Status:
Completed
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Avelumab
Axitinib